These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Anti-ulcer activity of cromakalim (BRL 34915), a potassium-channel opener, against experimentally induced gastric and duodenal ulcers in rats and guinea-pigs.
    Author: Goswami S, Jain S, Santani D.
    Journal: J Pharm Pharmacol; 1997 Feb; 49(2):195-9. PubMed ID: 9055194.
    Abstract:
    The effect of cromakalim, a potassium-channel opener, was studied on pylorus ligation-induced, aspirin-induced and water-immersion plus restraint stress-induced gastric ulcers in rats and on histamine-induced duodenal ulcer in guinea-pigs. Pretreatment with cromakalim (50-500 micrograms kg-1, p.o.) resulted in a significant reduction in the incidence of gastric and duodenal ulceration in each model. The anti-ulcer activity of cromakalim was comparable with that of cimetidine. Cromakalim at 100, 250 and 500 micrograms kg-1 caused a reduction in the volume of the gastric content in pylorus-ligated rats, and a dose of 250 micrograms kg-1 resulted in a significant reduction in total acidity (28.81 +/- 11.73 mEq L-1, P < 0.02) in the pylorus ligation model. A significant reduction in total acid output was observed at doses of 250 micrograms kg-1 (84.27 +/- 22.33 mEqH+, P < 0.02) and 500 micrograms kg-1 (120.17 +/- 24.49 mEqH+, P < 0.01) in pylorus-ligated rats. A significant reduction in the ulcer index in pylorus-ligated rats was observed at all cromakalim doses: 50 micrograms kg-1 (0.23 +/- 0.09, P < 0.05), 100 micrograms kg-1 (0.15 +/- 0.09, P < 0.02), 250 micrograms kg-1 (0.12 +/- 0.05, P < 0.01) and 500 micrograms kg-1 (0.14 +/- 0.03, P < 0.02). A significant reduction in the ulcer index of aspirin-treated rats was also observed at all cromakalim dose levels: 50 micrograms kg-1 (0.39 +/- 0.03, P < 0.01), 100 micrograms kg-1 (0.28 +/- 0.06, P < 0.01), 250 micrograms kg-1 (0.22 +/- 0.04, P < 0.001) and 500 micrograms kg-1 (0.28 +/- 0.03, P < 0.01). In the water-immersion plus restraint stress-induced gastric ulcer model, cromakalim significantly reduced gastric ulceration at all the dose levels: 50 micrograms kg-1 (28.2 +/- 2.12, P < 0.001), 100 micrograms kg-1 (20.24 +/- 1.71, P < 0.01), 250 micrograms kg-1 (19.95 +/- 1.46, P < 0.001) and 500 micrograms kg-1 (21.61 +/- 3.00, P < 0.001) but there was no consistent reduction of gastric bleeding. In addition to gastric ulcers, duodenal lesions were also reduced by pretreatment with cromakalim at all dose levels: 50 micrograms kg-1 (97.87 +/- 20.03 mm2, P < 0.02), 100 micrograms kg-1 (70.72 +/- 12.82 mm2, P < 0.02), 250 micrograms kg-1 (48.32 +/- 8.42 mm2, P < 0.01) and 500 micrograms kg-1 (55.50 +/- 12.50 mm2, P < 0.01). Cromakalim at a dose of 100 micrograms kg-1 also reduced total acidity (99.36 +/- 9.12 mEqL-1, P < 0.02) and total acid output (172.22 +/- 45.33 mEq of H+, P < 0.05) in this model. These findings demonstrate the anti-ulcer activity of cromakalim in different experimental models and suggest its potential use in ulcer therapy.
    [Abstract] [Full Text] [Related] [New Search]